Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2022 | What to look forward to at ASCO 2022

Parag Jasani • 30 May 2022
ASCO 2022
Chronic Lymphocytic Leukemia Leukemia

Parag Jasani, MBBS, MRCP, FRCPath, FRCP, University College Hospital, London, UK, on what he is looking forward to at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting 2022. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Parag Jasani

The key barrier to making the implementation of bispecific antibodies in CLL possible
0:41
The key barrier to making the implementation of bispecific antibodies in CLL possible
Parag Jasani • 14 Sep 2025
Investigating bispecific antibodies in CLL
1:00
Investigating bispecific antibodies in CLL
Parag Jasani • 14 Sep 2025
The potential of bispecific antibodies in CLL
1:04
The potential of bispecific antibodies in CLL
Parag Jasani • 14 Sep 2025
Personalizing CLL therapy in the frontline
0:56
Personalizing CLL therapy in the frontline
Parag Jasani • 10 Dec 2023

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Parag Jasani • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Parag Jasani • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Parag Jasani • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Parag Jasani • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals